検索ワード: ravimite ohutus (エストニア語 - 英語)

ravimite ohutus
safety of medicines

ravimite ohutus ja tõhusus
safety and efficacy of medicinal products

ohutus
safety

ohutus.
igos. 25-7.

muuta ravimite ohutus läbipaistvamaks;
increasing drug safety transparency;

inimtervishoius kasutatavate ravimite ja veterinaarravimite ohutus
safety of medicinal products for human and veterinary use

eesmärk on tagada jätkuvalt ravimite ohutus pärast müügiloa andmist.
the objective is to ensure the continuous safety of products once they are authorised.

Üks paljude küsimuste seast on kahtlemata patsiendi teavitamine ja ravimite ohutus.
one among very many issues is undoubtedly patient information and the safety of medicinal products.

nende ravimite efektiivsus ja ohutus koos fosamprenaviiri ja ritonaviiriga manustamisel ei ole kindlaks tehtud.
the efficacy and safety of these therapies with fosamprenavir and ritonavir has not been established.

viimased kahjulike kõrvaltoimetega seotud juhtumid näitavad, et ravimite ohutus on jätkuvalt suur tervishoiuprobleem.
recent events linked to adverse reactions demonstrate that the safety of medicines remains a major public health issue.

ribaviriini ja otsese toimega viirusevastaste ravimite kombinatsiooni ohutus ja efektiivsus neil patsientidel ei ole veel tõestatud.
the safety and efficacy of ribavirin used together with direct-acting-anti-virals in these patients has not been established.

inimtervishoius kasutatavate uuritavate ravimite kliiniliste uuringute läbiviimisel tuleb tagada uuringus osalejate ohutus ja õiguste kaitse.
in conducting clinical trials on investigational medicinal products for human use, the safety and the protection of the rights of trial subjects should be ensured.

seni vastu võetud ühenduse eeskirjad on aidanud tublisti kaasa sellele, et ühenduses turule lubatud ravimite ohutus on pideva jälgimise all.
community rules so far adopted have made a major contribution to the achievement of the objective that medicinal products authorised to be placed on the community market are continuously monitored as regards their safety.

nad varustavad vke-sid ja ülikoole vahendite ning metoodikatega, et tagada paremini ravimite ohutus ning tõhusus, intelligentne infrastruktuur ning teadmiste juhtimine.
they will involve the smes and universities by providing them with tools and methodologies to better predict the harmlessness and effectiveness of medicines, intelligent infrastructures and knowledge management.

ohutus patentravimite komitee (chmp) vaatas üle paroksetiini sisaldavate ravimite üldise ohutusprofiili.
safety the overall safety profile of paroxetine containing medicinal products was reviewed by the chmp.

samuti vaadatakse läbi farmaatsiatooteid käsitlev eli õiguslik raamistik, et tagada ravimite ohutus, patsientidele antav selge teave ning juurdepääs turvalistele, kuluefektiivsetele ja kvaliteetsetele tervishoiuteenustele ja -toodetele.
there will also be a review of the eu’s legal framework for pharmaceutical products to ensure the safety of medicines, clear information for patients and access to safe, cost-effective and high-quality health services and products.

sellest cyp2d6 toimest tingituna võivad cyp2d6 kaudu metaboliseeritavate ravimite toimeained kuhjuda ja/või aktiivsete metaboliitide moodustumine häiruda ning seetõttu võib nende ravimite ohutus ja/või efektiivsus muutuda, kui neid manustatakse koos nuedextaga (vt lõik 4.5).
because of this effect on cyp2d6, accumulation of parent drug substances and/or failure of active metabolite formation may affect the safety and/or the efficacy of medicinal products used concomitantly with nuedexta that are metabolised by cyp2d6 (see section 4.5).

sellele probleemile ei ole lihtsaid lahendusi, ning need, kes arvavad, et patsiendi ohutus ja ravimite ohutus on probleem ainult paralleelkaubanduse tõttu - vaatan saalis ülespoole, kuid paralleelkaubanduse vaate esindajate jaoks on kellaaeg vist liiga varajane - näevad probleemi liiga kitsalt ning solvavad nii minu kui ka mu kolleegidest parlamendiliikmete arusaamist.
there are no simple solutions to this problem, and those who believe that patient safety and the safety of medicinal products are an issue only with regard to parallel trade - i glance up at the gallery, but it is probably a little too early for the representatives of parallel trade - take too narrow a view and insult my intelligence and that of my fellow members.